A REVIEW ON FIRST MEMBERS OF COVID-19 VACCINES IN PHASE 3 AROUND THE GLOBE

Abstract

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), a member of the coronaviridae family is the cause of the pandemic which started in 2019 and the world is still fighting against it. In spite of the usage of drugs like remedesivir, flavinavir and hydroxycholoquine along with different approaches to increase the immunity or to treat the respiratory infection in humans, even now this viral infection is uncontrollable. According to the stats, till November 10, 2020 over 10 million people have lost their lives around the world, touching the mark of 37 mill ion plus patients around the world with epidemiology showing the most cases in USA followed by India, Russia, Brazil and Spain. After seeing the rapid spread and post disease effects of this air borne viral infection, an urgent need of the vaccine consider ed. This led to encourage researchers around the world to develop different types of vaccines, namely inactivated, live attenuated, nanoparticle based, viral vectored, recombinant type, DNA and RNA vaccines, among which few have already passed Phase 1 clinical trials and are under Phase 2 or 3 human trials. The vaccines which have the highest potential to be successful with minimal side effects proposed by different countries around the world with their type, mechanism of action and their effects along with the challenges and considerations regarded with these vaccines has been discussed in this paper.